From In Vitro To In Vivo: Hypoxia Attenuates Replicative Senescence And Preserves Therapeutic Activity In Long-Term Passaged Human Umbilical Cord-Derived Mesenchymal Stem Cells
Mesenchymal stem cells (MSCs) hold immense promise for treating various diseases and injuries, particularly in regenerative medicine. However, a significant hurdle in their clinical application is that these cells tend to age and lose their healing capabilities when grown in large numbers outside the body, a process called ex vivo expansion. This aging, or “replicative senescence,” limits their effectiveness and the quantity available for therapies.
Recent research explored a novel approach to overcome this challenge by mimicking the natural low-oxygen environment (hypoxia) where stem cells often reside in the body. Scientists compared growing human umbilical cord-derived mesenchymal stem cells (hUC-MSCs) in standard oxygen levels (normoxia) versus a reduced oxygen environment.
The findings were remarkable. Cells cultured under low-oxygen conditions demonstrated superior performance. They maintained their ability to develop into different cell types, exhibited enhanced growth, and secreted more beneficial factors that aid in tissue repair. Crucially, the hypoxic environment significantly reduced cellular aging, minimized DNA damage, and decreased the release of inflammatory molecules that can harm tissues. It also helped prevent premature cell death.
Even more compelling were the results from animal studies. When these specially cultured stem cells (after many rounds of lab growth) were transplanted into mice with diabetic kidney disease, they significantly improved kidney function and reduced scarring.
This research provides a crucial step forward, suggesting that optimizing the oxygen levels during stem cell expansion can preserve their youthful properties and therapeutic potential, paving the way for more effective and scalable stem cell-based treatments.
Source: link to paper